Tag: pharmaceutical stocks

Market News

3 Stocks Thriving in a Mixed Market: One to Avoid

Which stocks are winning in today’s shaky market? We dive into 3 top performers and reveal one to avoid. Curious...

07/08/2025

2 views

Read More

Market News

Why Lilly’s Weight-Loss Pill Shook Markets

Lilly’s stock crashed after its weight-loss pill underperformed. But with stellar Q2 results, is this a buying opportunity or a...

07/08/2025

4 views

Read More

Market News

Eli Lilly’s Q2 2025: Mounjaro, Zepbound Drive Growth

Eli Lilly's Q2 2025 earnings beat expectations with blockbuster drug sales. But what’s next for their obesity pill trials? Click...

07/08/2025

3 views

Read More

Market News

Eli Lilly Earnings: What to Expect in Q2 2025

Will Eli Lilly's Q2 earnings soar with Zepbound's success? Analysts predict big wins, but what about CVS's Wegovy move? Click...

06/08/2025

24 views

Read More

Market News

Novo Nordisk Q2 2025: Sales Surge, Challenges Loom

Novo Nordisk's Q2 2025 earnings reveal a 13% sales jump, but a slashed outlook and new CEO spark debate. What's...

06/08/2025

17 views

Read More

Market News

Why Novo Nordisk’s GLP-1 Growth Is Slowing: Key Insights

Novo Nordisk’s Ozempic is losing ground in the GLP-1 market. What’s behind the slowdown, and can it recover? Dive into...

05/08/2025

10 views

Read More

Market News

Compounded GLP-1s: Impact On Health And Markets

Over a million Americans use unapproved GLP-1 drugs, shaking up markets and health. What’s next for investors and patients? Click...

31/07/2025

3 views

Read More

Market News

Why Novo Nordisk Shares Plunged: Obesity Drug Market Woes

Novo Nordisk’s shares tanked after a slashed forecast. Compounded GLP-1 drugs are eating into Wegovy’s market. Is this a dip...

29/07/2025

3 views

Read More

Global Markets

5 Key Market Moves to Watch This Week

Markets soar as geopolitics and oil prices shift. What's driving stocks and what's next for investors? Dive into the top...

24/06/2025

0 views

Read More

Market News

Biotech IPO Slump: Navigating Challenges Until 2026

The biotech IPO market is frozen, with headwinds from regulations and pricing policies. Will 2026 bring a thaw, or are...

29/05/2025

28 views

Read More